Connect Biopharma Holdings Ltd is a biotechnology business based in the US. Connect Biopharma shares (CNTB) are listed on the NASDAQ and all prices are listed in US Dollars. Connect Biopharma employs 108 staff and has a market cap (total outstanding shares value) of 0.00.
How to buy shares in Connect Biopharma
- Compare share trading platforms. Use our comparison table to help you find a platform that fits you.
- Open your brokerage account. Complete an application with your details.
- Confirm your payment details. Fund your account.
- Research the stock. Find the stock by name or ticker symbol – CNTB – and research it before deciding if it's a good investment for you.
- Purchase now or later. Buy your desired number of shares with a market order or use a limit order to delay your purchase until the stock reaches a desired price.
- Check in on your investment. Optimize your portfolio by tracking your stock.
Our top pick for
Beginners

Our top pick for
Building a portfolio

Our top pick for
Advanced traders

Connect Biopharma stock price (NASDAQ: CNTB)
Use our graph to track the performance of CNTB stocks over time.Connect Biopharma shares at a glance
Latest market close | $0.90 |
---|---|
52-week range | $0.56 - $29.27 |
50-day moving average | $1.27 |
200-day moving average | $7.06 |
Wall St. target price | $11.12 |
PE ratio | N/A |
Dividend yield | $0 (0%) |
Earnings per share (TTM) | $-3.74 |
Buy Connect Biopharma shares from these brokerages
Compare special offers, low fees and a wide range of types of investments among top trading platforms.*Signup bonus information updated weekly.
The value of any investment can go up or down depending on news, trends and market conditions. We are not investment advisers, so do your own due diligence to understand the risks before you invest.
Is it a good time to buy Connect Biopharma stock?
The technical analysis gauge below displays real-time ratings for the timeframes you select. This is not a recommendation, however. It represents a technical analysis based on the most popular technical indicators: Moving Averages, Oscillators and Pivots. Finder might not concur and takes no responsibility.
This chart is not advice or a guarantee of success. Rather, it gauges the real-time recommendations of three popular technical indicators: moving averages, oscillators and pivots. Finder is not responsible for how your stock performs.
Connect Biopharma price performance over time
Historical closes compared with the close of $0.9045 from 2022-07-01
1 week (2022-06-24) | 0.50% |
---|---|
1 month (2022-06-02) | 14.48% |
3 months (2022-04-01) | -70.34% |
6 months (2021-12-31) | -82.44% |
1 year (2021-07-02) | -95.41% |
---|---|
2 years (2020-06-28) | N/A |
3 years (2019-06-28) | N/A |
5 years (2017-06-28) | N/A |
Connect Biopharma financials
Gross profit TTM | $0 |
---|---|
Return on assets TTM | -26.72% |
Return on equity TTM | -367.66% |
Profit margin | 0% |
Book value | $31.52 |
Market capitalisation | $49.6 million |
TTM: trailing 12 months
Connect Biopharma share dividends
We're not expecting Connect Biopharma to pay a dividend over the next 12 months.
You may also wish to consider:
- Gilead Sciences (GILD.US) (4.63% forward annual dividend yield)
- Amgen (AMGN.US) (3.25% forward annual dividend yield)
Connect Biopharma overview
Connect Biopharma Holdings Limited, a clinical-stage biopharmaceutical company, focuses on the discovery and development of immune modulators for the treatment of serious autoimmune diseases and inflammation. The company's lead product candidate is CBP-201, an anti-interleukin-4 receptor alpha antibody, which is in Phase IIb clinical trial for the treatment of inflammatory allergic diseases, such as atopic dermatitis, asthma, and chronic rhinosinusitis with nasal polyps. Its products also comprise CBP-307, a small molecule modulator of sphingosine 1-phosphate receptor 1, a regulator of T cell mobilization out of lymph nodes into the periphery that is in Phase II for the treatment of autoimmune-related inflammation diseases; CBP-174, a small molecule histamine receptor 3 antagonist for oral administration, which is in a preclinical stage to treat chronic itch associated with skin inflammation; and CBP-233, a preclinical stage humanized antibody against interleukin-33, a cytokine involved in T helper 2 inflammation. The company was founded in 2012 and is headquartered in Taicang, China. .
Connect Biopharma in the news
Connect Biopharma Announces Receipt of NASDAQ Deficiency Notice Regarding Minimum Bid Price Requirement
Frequently asked questions
What percentage of Connect Biopharma is owned by insiders or institutions?Currently 14.454% of Connect Biopharma shares are held by insiders and 32.31% by institutions. How many people work for Connect Biopharma?
Latest data suggests 108 work at Connect Biopharma. When does the fiscal year end for Connect Biopharma?
Connect Biopharma's fiscal year ends in December. Where is Connect Biopharma based?
Connect Biopharma's address is: East R&D Building, Taicang, China, 215400 What is Connect Biopharma's ISIN number?
Connect Biopharma's international securities identification number is: US2075231017
More guides on Finder
-
How to buy Intchains Group (ICG) stock when it goes public
Everything we know about the Intchains Group IPO, plus information on how to buy in.
-
How to buy Biostage (BSTG) stock when it goes public
Everything we know about the Biostage IPO, plus information on how to buy in.
-
How to buy Wang & Lee Group (WLGS) stock when it goes public
Everything we know about the Wang & Lee Group IPO, plus information on how to buy in.
-
How to buy OptMed (OMED) stock when it goes public
Everything we know about the OptMed IPO, plus information on how to buy in.
-
How to buy Lichen China (LICN) stock when it goes public
Everything we know about the Lichen China IPO, plus information on how to buy in.
-
How to buy LeeWay Services stock when it goes public
Everything we know about the LeeWay Services IPO, plus information on how to buy in.
-
How to buy Nano Labs (NA) stock when it goes public
Everything we know about the Nano Labs IPO, plus information on how to buy in.
-
How to buy Warrantee (WRNT) stock when it goes public
Everything we know about the Warrantee IPO, plus information on how to buy in.
-
How to buy Treasure Global (TGL) stock when it goes public
Everything we know about the Treasure Global IPO, plus information on how to buy in.
-
How to buy BIOLIFE4D (SAVU) stock when it goes public
Everything we know about the BIOLIFE4D IPO, plus information on how to buy in.
Ask an Expert